DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: GDC-1971
Drug: Osimertinib
Drug: Cetuximab

First Posted Date: 2023-07-20

Last Posted Date: 2025-02-27

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 172

Registration Number: NCT05954871

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States

and more 8 locations

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Cevostamab
Drug: Elranatamab
Drug: Tocilizumab

First Posted Date: 2023-07-03

Last Posted Date: 2025-03-28

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 120

Registration Number: NCT05927571

Locations: 🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
The Alfred Hospital, Prahan, Victoria, Australia

and more 6 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Non-small Cell Lung Cancer
Gastric Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RO7496353
Drug: Capecitabine
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: S-1
Drug: Gemcitabine
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2023-05-19

Last Posted Date: 2025-04-01

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT05867121

Locations: 🇹🇷
Ege University Medical Faculty, Izmir, Turkey
🇹🇷
Dokuz Eylul Universitesi Tip Fakultesi, Lzmir, Turkey
🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States

and more 27 locations

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Phase 1

Recruiting

Conditions: Advanced Prostate Cancer
Metastatic Prostate Cancer

Interventions: Drug: RO7656594

First Posted Date: 2023-04-05

Last Posted Date: 2025-05-04

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 160

Registration Number: NCT05800665

Locations: 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 22 locations

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Phase 2

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Systemic Sclerosis With Lung Involvement

Interventions: Drug: Vixarelimab
Drug: Placebo

First Posted Date: 2023-03-27

Last Posted Date: 2025-05-15

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 320

Registration Number: NCT05785624

Locations: 🇦🇷
Instituto De Patologias Respiratorias, San Miguel de Tucuman, Argentina
🇦🇷
Centro de Investigaciones Medicas Tucuman, San Miguel de Tucuman, Argentina
🇦🇷
Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina

and more 110 locations

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Phase 1

Terminated

Conditions: Acute Graft-versus-host Disease

Interventions: Drug: GDC-8264

First Posted Date: 2023-01-06

Last Posted Date: 2025-04-24

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 7

Registration Number: NCT05673876

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Massachusetts General Hospital; Harvard Medical School - Gi Unit Grj724, Boston, Massachusetts, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 5 locations

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Phase 2

Completed

Conditions: Chronic Refractory Cough (CRC) With Non-atopic Asthma
CRC With Atopic Asthma
Unexplained Chronic Cough
CRC With Chronic Obstructive Pulmonary Disease
CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Interventions: Drug: GDC-6599
Other: GDC-6599-matching placebo
Diagnostic Test: Mannitol

First Posted Date: 2022-12-21

Last Posted Date: 2024-12-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 80

Registration Number: NCT05660850

Locations: 🇦🇺
Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia
🇺🇸
Southern California Institute For Respiratory, Los Angeles, California, United States
🇬🇧
Queen Anne Street Medical Centre, London, United Kingdom

and more 17 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cevostamab
Drug: XmAb24306
Drug: Tocilizumab

First Posted Date: 2022-12-12

Last Posted Date: 2025-05-09

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 90

Registration Number: NCT05646836

Locations: 🇦🇺
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇩🇰
Sygehus Lillebaelt - Vejle Sygehus, Vejle, Denmark

and more 10 locations

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)

Phase 2

Recruiting

Conditions: Geographic Atrophy

Interventions: Biological: OpRegen

First Posted Date: 2022-11-23

Last Posted Date: 2025-04-27

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 60

Registration Number: NCT05626114

Locations: 🇮🇱
Hadassah MC, Jerusalem, Israel
🇮🇱
Tel Aviv Sourasky MC, Tel Aviv, Israel
🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States

and more 4 locations

A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives

Completed

Conditions: Specialist Referral: Oncology
Specialist Referral: Neurology
Specialist Referral: Ophthalmology

Interventions: Other: No Intervention

First Posted Date: 2022-11-22

Last Posted Date: 2025-04-25

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 84

Registration Number: NCT05624788

Locations: 🇺🇸
PPD Virtual - PPD - US, Wilmington, North Carolina, United States
🇺🇸
Avera Research Institute, Sioux Falls, South Dakota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy